Washington, DC—The combination of nivolumab plus ipilimumab improved survival compared with ipilimumab alone in patients with previously untreated advanced melanoma, according to updated results of the phase 3 CheckMate-067 clinical trial presented at the 2017 meeting of the American Association for Cancer Research. A descriptive analysis suggested that the combination was superior to nivolumab monotherapy, although that was not a prespecified end point of the study.
As new drugs are introduced into the clinic, an active area of research is the identification of biomarkers for response that would inform oncologists about which patients are likely to respond.
Abemaciclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, achieved an objective response in 1 of 5 heavily pretreated patients with metastatic hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.
Results 1 - 3 of 3